Trellis Vitality Review: $150/mo Semaglutide

Most GLP-1 pricing pages show you one number and make you guess what it is attached to. Trellis Vitality (trellisvitality.com) publishes a table — one month, three months, six months, both molecules, all four columns visible without an intake. We checked it in August 2026. The GLP-1 half is the best-formed price surface in this batch of seven. The other half of the catalogue is a hole.

The table, which is the whole reason to read this

Semaglutide is $150 a month paying monthly, $140 a month on a three-month plan and $133 a month on six. Tirzepatide is $199, $189 and $179 across the same three rungs.¹ The page labels the figures "per-month price; longer plans cost less per month", and states that all dosages cost the same.

The thing that matters there is the first column. It exists, it is labelled, and it is the month-to-month rate. That sounds like a low bar until you have read enough of these pages: the common trick is to publish only the longest-commitment rung and print it with a "/mo" after it, so a twelve-month prepay masquerades as a monthly rate. That structure — and how to spot it in about thirty seconds — is the subject of the teaser-rate trap. Trellis does not do it.

Six months, both ways

Semaglutide costs $900 over six months if you pay monthly and keep the option to leave, or $798 if you commit up front. The difference is $102 across half a year — about $17 a month for the right to stop. Tirzepatide is $1,194 monthly against $1,074 committed, a $120 difference.

Those are small enough spreads that the commitment rung is not really the story. The story is that $150 month to month is genuinely cheap for compounded semaglutide with no lock-in, and it is $59 a month under The Edit's $209 — a $354 gap over six months, from a company that shares The Edit's medical group.

⚠ The part of the catalogue that has no price

Trellis sells five programs. Only one of them has a ladder.

NAD+ is published as "treatment plans starting at $129 a month". Glutathione is "starting at $93". Lipo-MIC plus B12 is "starting at $130". Tesamorelin is "starting at $299".¹ For all four, there is no rung table anywhere — not on the program page, not in the site's build output, and not in the intake payload, all of which we pulled.

So we will say what we can defend and nothing more: those are **from** prices with no ladder published. Do not treat $129 as Trellis's monthly NAD+ rate, because we do not know that it is. Given that the GLP-1 table's six-month rung sits about 11% below its one-month rung — 11.3% on semaglutide, 10.1% on tirzepatide — it is a reasonable guess that the four "starting at" figures are the longest-commitment rungs and the monthly rate is higher — but that is an inference, and inferences do not go on a price board. If NAD+ is what you are shopping for, you will have to ask.

There is a related irritation worth flagging, because it is the sort of thing that erodes trust in the numbers that *are* good: Trellis's own blog states twice that the company publishes its complete pricing on the program page. It does not. Only the GLP-1 page does.

The same page furniture carries a star rating, a patient count and an average-annual-savings claim, none of which is sourced anywhere on the site. We do not repeat unsourced marketing statistics, so you will not find those numbers here.

Who is behind it

The pharmacy is named: VialsRX, a state-licensed compounding pharmacy in Houston, Texas, identified in the site's own machine-readable disclosure file. Naming a pharmacy is the single most useful thing a compounded-GLP-1 seller can do, and most of this cohort does not — see how to verify a compounding pharmacy is legitimate for what you can actually do once you have a name.

The medical group is Arora Health & Aesthetics, LLC, under medical director Dr. Sean Arora, whose NPI 1841729449 verifies as active in the federal registry.² That is the same medical group and the same medical director as The Edit. Different pharmacy, different prices, separable products — but if you are lining the two up as competing clinical options, be aware you are looking at one clinical operation with two storefronts.

What is not disclosed is the corporate entity. The terms page runs to about three kilobytes of text and never names an LLC or a corporation. Coverage is claimed as all 50 states.

The regulatory screen

The trading name, the medical group and the named pharmacy all returned zero company-column matches in the FDA's live warning-letter index in August 2026.³ The pass included a positive control — a real February 2026 letter to an unrelated telehealth seller — which returned correctly, so the clean result is evidence rather than silence.

The verdict for a bargain hunter

For semaglutide or tirzepatide, this is one of the better deals we have priced: $150 and $199 month to month, a published ladder, a named pharmacy, a checkable prescriber, and no prepay illusion in any column. Line it up against everything else on the semaglutide price ladder and the tirzepatide board before you commit, and remember that the only provider in this batch with a cheaper standard-dose month-to-month semaglutide rung — Pepti at $99 — carries a pricing contradiction we could not resolve. For NAD+ or anything else on the Trellis shelf, there is no price to compare, and the honest advice is to ask for the full ladder in writing before you start. The reasoning behind all of it sits in our research library.